The Immunosuppressants market in Romania has been experiencing growth in recent years.
Customer preferences: Patients in Romania who suffer from autoimmune diseases, such as rheumatoid arthritis and lupus, are the primary consumers of immunosuppressants. These drugs help to suppress the immune system, which can attack healthy cells in the body. Patients who have undergone organ transplants also require immunosuppressants to prevent their immune systems from rejecting the new organ.
Trends in the market: The Romanian government has been increasing its healthcare budget in recent years, which has led to an increase in the availability of immunosuppressants. Additionally, there has been a rise in the number of organ transplants being performed in Romania, which has led to an increase in demand for immunosuppressants. The market has also seen an increase in the use of biosimilars, which are cheaper alternatives to brand-name immunosuppressants.
Local special circumstances: Romania has a high prevalence of autoimmune diseases, which has contributed to the growth of the immunosuppressants market. Additionally, the country has a shortage of organ donors, which has led to an increase in the use of living donors. This has resulted in a higher demand for immunosuppressants to prevent the recipient's immune system from rejecting the donated organ.
Underlying macroeconomic factors: Romania has been experiencing economic growth in recent years, which has led to an increase in healthcare spending. The country's aging population has also contributed to the growth of the immunosuppressants market, as older individuals are more likely to suffer from autoimmune diseases. However, there are concerns about the sustainability of Romania's healthcare system, which could impact the growth of the immunosuppressants market in the future.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
